PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma

被引：0
|
作者：
Yael Babichev
Leah Kabaroff
Alessandro Datti
David Uehling
Methvin Isaac
Rima Al-awar
Michael Prakesch
Ren X. Sun
Paul C. Boutros
Rosemarie Venier
Brendan C. Dickson
Rebecca A. Gladdy
机构：
[1] Mount Sinai Hospital,Lunenfeld
[2] Lunenfeld-Tanenbaum Research Institute,Tanenbaum Research Institute
[3] University of Perugia,Sinai
[4] Ontario Institute for Cancer Research,McLaughlin Assay and Robotic Technologies Facility
[5] University of Toronto,Department of Agricultural, Food, and Environmental Sciences
[6] Ontario Institute for Cancer Research,Drug Discovery Group
[7] University of Toronto,Department of Pharmacology and Toxicology
[8] Mount Sinai Hospital,Informatics and Biocomputing Program
[9] University of Toronto,Department of Medical Biophysics
[10] University of Toronto,Department of Pathology and Laboratory Medicine
[11] Ontario Institute for Cancer Research,Department of Surgery
[12] Lunenfeld-Tanenbaum Research Institute,Institute of Medical Science
来源：
Journal of Translational Medicine | / 14卷
关键词：
Leiomyosarcoma; PI3K; mTOR; Drug discovery; Sarcoma; Doxorubicin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] PI3K/Akt/mTOR inhibitors in breast cancer
    Joycelyn JX Lee
    Kiley Loh
    Yoon-Sim Yap
    Cancer Biology & Medicine, 2015, (04) : 342 - 354
  • [42] PI3K/Akt/mTOR inhibitors in breast cancer
    Lee, Joycelyn J. X.
    Loh, Kiley
    Yap, Yoon-Sim
    CANCER BIOLOGY & MEDICINE, 2015, 12 (04) : 342 - 354
  • [43] Targeting PI3K/AKT/mTOR-mediated autophagy for tumor therapy
    Zhenru Xu
    Xu Han
    Daming Ou
    Ting Liu
    Zunxiong Li
    Guanmin Jiang
    Jing Liu
    Ji Zhang
    Applied Microbiology and Biotechnology, 2020, 104 : 575 - 587
  • [44] Targeting PI3K/AKT/mTOR-mediated autophagy for tumor therapy
    Xu, Zhenru
    Han, Xu
    Ou, Daming
    Liu, Ting
    Li, Zunxiong
    Jiang, Guanmin
    Liu, Jing
    Zhang, Ji
    APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, 2020, 104 (02) : 575 - 587
  • [45] PI3K/AKT/MTOR SIGNALING IN OLIGODENDROCYTE DIFFERENTIATION
    Wood, T. L.
    Tyler, W. A.
    Gangoli, N.
    Gokina, P.
    Kim, H. A.
    Covey, M.
    Levison, S. W.
    JOURNAL OF NEUROCHEMISTRY, 2009, 110 : 141 - 141
  • [46] THE PI3K/AKT MTOR PATHWAY IN OLIGODENDROCYTE DIFFERENTIATION
    Wood, T.
    Tyler, W.
    Gangoli, N.
    Gokina, P.
    Kim, H.
    Covey, M.
    Levison, S.
    GLIA, 2009, 57 (13) : S20 - S20
  • [47] PI3K/AKT/mTOR Inhibitors In Ovarian Cancer
    Mazzoletti, M.
    Broggini, M.
    CURRENT MEDICINAL CHEMISTRY, 2010, 17 (36) : 4433 - 4447
  • [48] PI3K/Akt/mTOR inhibitors in breast cancer
    Joycelyn JX Lee
    Kiley Loh
    Yoon-Sim Yap
    Cancer Biology & Medicine, 2015, 12 (04) : 342 - 354
  • [49] The Role of PI3K/mTOR Inhibition in Combination with Sorafenib in Hepatocellular Carcinoma Treatment
    Gedaly, Roberto
    Angulo, Paul
    Chen, Changguo
    Creasy, Kate Townsend
    Spear, Brett T.
    Hundley, Jonathan
    Daily, Michael F.
    Shah, Malay
    Evers, B. Mark
    ANTICANCER RESEARCH, 2012, 32 (07) : 2531 - 2536
  • [50] PI3K/AKT/mTOR pathway inhibition sensitizes ovarian cancer cells to anti-estrogen therapy
    McIlwain, C. A.
    Prince, V. M.
    Tan, L.
    Whitehead, C.
    Leopold, J.
    McLean, K.
    GYNECOLOGIC ONCOLOGY, 2018, 149 : 70 - 71
12345